Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Reduction of tumor burden and stabilization of disease by systemic therapywith anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma
Autore:
Heinzerling, LM; Urbanek, M; Funk, JO; Peker, S; Bleck, O; Neuber, K; Burg, G; von den Driesch, P; Dummer, R;
Indirizzi:
Univ Zurich Hosp, Dermatol Klin, Dept Dermatol, CH-8091 Zurich, Switzerland Univ Zurich Hosp Zurich Switzerland CH-8091 CH-8091 Zurich, Switzerland Univ Hosp Erlangen Nurnberg, Dept Dermatol, Erlangen, Germany Univ Hosp Erlangen Nurnberg Erlangen Germany ermatol, Erlangen, Germany Univ Hamburg Hosp, Dept Dermatol, D-2000 Hamburg, Germany Univ Hamburg Hosp Hamburg Germany D-2000 rmatol, D-2000 Hamburg, Germany
Titolo Testata:
CANCER
fascicolo: 8, volume: 89, anno: 2000,
pagine: 1835 - 1844
SICI:
0008-543X(20001015)89:8<1835:ROTBAS>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
NON-HODGKINS-LYMPHOMA; BCL-2 PROTEIN EXPRESSION; MONOCLONAL-ANTIBODY; LOW-GRADE; RHEUMATOID-ARTHRITIS; RANDOMIZED TRIAL; CLINICAL-TRIAL; FOLLOW-UP; IDEC-C2B8; CANCER;
Keywords:
cutaneous B-cell lymphoma; large B-cell lymphoma of the leg; LBLL; therapy; CD20; rituximab; intravenous; chimeric antibody;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Dummer, R Univ Zurich Hosp, Dermatol Klin, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland Univ Zurich Hosp Gloriastr 31 Zurich SwitzerlandCH-8091 erland
Citazione:
L.M. Heinzerling et al., "Reduction of tumor burden and stabilization of disease by systemic therapywith anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma", CANCER, 89(8), 2000, pp. 1835-1844

Abstract

BACKGROUND, Primary cutaneous B-cell lymphoma (CBCL) is characterized by restriction to the skin, a high incidence of recurrence after various treatment modalities, and a variable but mostly favorable prognosis. METHODS. Ten patients with long standing primary CBCL (3 with follicular CBCL, 5 with cutaneous, large B-cell lymphoma, 1 with diffuse large cell lymphoma, and 1 with extranodal large cell lymphoma) were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen that is present on malignant and normal B-cells. In 6 of 10 patients, several treatment attempts either had failed or could not be used due to severe side effects or underlying disease. RESULTS. The treatment regimen resulted in two complete regressions, five partial responses, and one mixed response, and two patients did not respondto the treatment. No severe side effects occurred, except for slight pain in the nodules after infusion and an urticarial reaction at the tumor sites. A prolonged, complete disappearance of B-cells from the peripheral blood was observed. The immunoglobulin serum levels and inflammatory markers wereunchanged. Histologic examination of biopsies from two regressing tumor nodes showed necrotic tumor cells and infiltration with CD8 positive cells. CONCLUSIONS, Intravenous therapy with the anti-CD20 antibody rituximab is a nontoxic and effective treatment for patients with primary cutaneous B-cell lymphoma. Cancer 2000;89:1835-44. (C) 2000 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 18:25:20